All Stories

  1. Evaluating a custom GPT assistant for critical appraisal of biological variation studies by the BIVAC
  2. Thyroid hormone profile and biological variation in a population of athletes during an entire sport season
  3. Novel biomarkers in bone pathophysiology: Establishing reference intervals and biological variations estimates for serum leptin, sclerostin, lipocalin-2, osteoprotegerin, resistin and Dickkopf-related protein-1 from the European biological variation st...
  4. Biological variation data. What's new.
  5. Systematic review and meta-analysis of biological variation data of urine albumin, albumin to creatinine ratio and other markers in urine
  6. The biological variation of insulin resistance markers: data from the European Biological Variation Study (EuBIVAS)
  7. A standard to report biological variation data studies – based on an expert opinion
  8. Corrigendum to “The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men” [Clin. Chim. Acta 555 (2024) 117806]
  9. A New Concept for Reference Change Values—Regression to the Population Mean
  10. Analytical performance specifications based on biological variation data – considerations, strengths and limitations
  11. The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men
  12. Sex-related differences in within-subject biological variation estimates for 22 essential and non-essential amino acids
  13. Biological variation of inflammatory and iron metabolism markers in high-endurance recreational athletes; are these markers useful for athlete monitoring?
  14. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
  15. Biological variation estimates of Alzheimer’s disease plasma biomarkers in healthy individuals
  16. Biological variation: recent development and future challenges
  17. Critical review and meta-analysis of biological variation estimates for tumor markers
  18. Long-term within- and between-subject biological variation of 29 routine laboratory measurands in athletes
  19. Biological variation estimates of thyroid related measurands – meta-analysis of BIVAC compliant studies
  20. Evidence-Based Introduction of Large-Scale Medical Technology Into Healthcare Through Test of Chance and Proof of Concept
  21. The European Biological Variation Study (EuBIVAS): a summary report
  22. Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study
  23. Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B12 and Active-B12® (holotranscobalamin) in the diagnosis of vitamin B12 deficiency
  24. Biological Variation of Cardiac Troponins in Health and Disease: A Systematic Review and Meta-analysis
  25. Critical appraisal and meta-analysis of biological variation estimates for kidney related analytes
  26. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters
  27. Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care
  28. Biological variation data for lipid cardiovascular risk assessment biomarkers. A systematic review applying the biological variation data critical appraisal checklist (BIVAC)
  29. European Biological Variation Study (EuBIVAS): Within- and Between-Subject Biological Variation Data for 15 Frequently Measured Proteins
  30. Systematic review of the biological variation data for diabetes related analytes
  31. The EuBIVAS: Within- and Between-Subject Biological Variation Data for Electrolytes, Lipids, Urea, Uric Acid, Total Protein, Total Bilirubin, Direct Bilirubin, and Glucose
  32. PTU-132 Normal alt – missed opportunities to find fibrosis. lessons from ILFT
  33. Within-subject and between-subject biological variation estimates of 21 hematological parameters in 30 healthy subjects
  34. Intelligent liver function diagnostic pathway – Relevance of alanine transaminase normal values
  35. Harmonization initiatives in the generation, reporting and application of biological variation data
  36. Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the ‘intelligent LFT’ pathway for the automated assessment of deranged liver enzymes
  37. Intelligent Liver Function Testing (iLFT): A Trial of Reflex Testing, Automated Diagnosis and Staging of Liver Disease
  38. A Critical Appraisal Checklist (BIVAC), to evaluate paper on Biological Variation
  39. Biological variation of serum creatinine
  40. Biological Variation Estimates Obtained from 91 Healthy Study Participants for 9 Enzymes in Serum
  41. Sample collections from healthy volunteers for biological variation estimates’ update: a new project undertaken by the Working Group on Biological Variation established by the European Federation of Clinical Chemistry and Laboratory Medicine
  42. Biological variation: a still evolving facet of laboratory medicine
  43. A checklist for critical appraisal of studies of biological variation
  44. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and γ-glutamyl transferase
  45. The following abstracts were presented at the Annual Scientific Meeting of the Scottish Intensive Care Society in St Andrews, January 2012
  46. Reflex and reflective testing: efficiency and effectiveness of adding on laboratory tests
  47. UK Consensus Conference on Early Chronic Kidney Disease 6 and 7 February 2007
  48. Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activityin VivoLimits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis
  49. Association between the cholesteryl ester transfer protein TaqI-detectable B polymorphism and low high-density lipoprotein cholesterol concentration in Saudis
  50. Serum leptin is elevated in Saudi Arabian patients with metabolic syndrome and coronary artery disease
  51. 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone
  52. Cardiovascular risk assessment in patients with retinal vein occlusion
  53. Osteoblastic 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Increases With Age and Glucocorticoid Exposure
  54. Role of leptin in glucose metabolism in type 2 diabetes
  55. Serum homocysteine concentration is related to diabetes mellitus, but not to coronary heart disease, in Saudi Arabians
  56. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus
  57. The sleep apnoea/hypopnoea syndrome depresses waking vagal tone independent of sympathetic activation
  58. Comparative accuracy of cardiovascular risk prediction methods in primary care patients
  59. Assessment of coronary heart disease risk prediction in general practice-which table?
  60. Standardization of HbA1c measurements
  61. Laboratory‐based calculation of coronary heart disease risk in a hospital diabetic clinic
  62. Plasma total homocysteine measurement by ion-paired reversed-phase hplc with electrochemical detection
  63. Glomerular filtration rate determination in diabetic patients using iohexol clearance — comparison of single and multiple plasma sampling methods
  64. The value of screening for Down's syndrome in a socioeconomically deprived area with a high ethnic population
  65. A Non-Isotopic Method for Estimating 11β Hydroxysteroid Dehydrogenase Activity In Vivo
  66. Ethnic differences in outcome of serum screening for Down's syndrome
  67. Measurement presents technical difficulties
  68. Plasma angiotensin-converting enzyme activity and carotid wall thickening.
  69. Serum screening for Down's syndrome. Vacutainer system can lead to inaccurate results.
  70. Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia
  71. Re‐evaluation of the captopril test for the diagnosis of primary hyperaldosteronism
  72. A case of skin hyperpigmentation due to α-MSH hypersecretion
  73. Interference of Fluorescein with Creatinine Assays
  74. Effects of mobile phase composition on the chromatographic and electrochemical behaviour of catecholamines and selected metabolites
  75. DOSE REGIMENS OF HUMAN GROWTH HORMONE: EFFECTS OF CONTINUOUS INFUSION AND OF A GELATIN VEHICLE ON GROWTH IN RATS AND RATE OF ABSORPTION IN RABBITS
  76. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication
  77. 2.4 Biological variation data: the need for appraisal of the evidence base